Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

Cannot have received: local therapy to liver (ablation other than radiofrequency or microwave ablation, i.e., alcohol ablation, transcatheter chemoembolization, transcatheter embolization, hepatic arterial infusion, local radiation/Stereotactic Body Radiation Therapy or radioembolization)

Has received local therapy to liver, ablation other than radiofrequency or microwave ablation (i.e., alcohol ablation, transcatheter chemoembolization, transcatheter embolization, hepatic arterial infusion, local radiation/Stereotactic Body Radiation Therapy or radioembolization) less than 3 months prior to treatment

Cannot have received: antineoplastic systemic chemotherapy or biological therapy

Antineoplastic systemic chemotherapy or biological therapy less than 21 days from treatment or 5 drug elimination half-lives, whichever is shorter prior to randomization

Cannot have received: immunotherapy

Exception: immunotherapy specified in this protocol

Immunotherapy not specified in this protocol less than 21 days from treatment or 5 drug elimination half-lives, whichever is shorter prior to randomization

Cannot have received: systemic glucocorticoids

Exception: inhaled or topical steroids allowed; systemic steroids at doses ≤10 mg/day prednisone or equivalent allowed; steroids may be used for premedication prior to imaging

Systemic glucocorticoids for any purpose other than to modulate symptoms from an adverse event (AE) that is suspected to have an immunologic etiology. Inhaled or topical steroids are allowed, and systemic steroids at doses ≤10 mg/day prednisone or equivalent are allowed. Exception: steroids may be used for premedication prior to imaging